Changes in the costs of treating mental health disorders - An overview of recent research findings

被引:5
作者
Berndt, ER
机构
[1] MIT, Alfred P Sloan Sch Management, Cambridge, MA 02142 USA
[2] Natl Bur Econ Res, Cambridge, MA 02142 USA
关键词
D O I
10.2165/00019053-200422002-00005
中图分类号
F [经济];
学科分类号
02 ;
摘要
This article reviews recent evidence on changes over time in the direct medical costs of treating three of the more common mental health disorders in the US: the acute (16-week) phase of major depressive disorder, the ongoing treatment of schizophrenia, and the ongoing treatment of bipolar I disorders. The three studies discussed in this article cover various time intervals over the decade from 1991 through 2000, and encompass both private sector and governmental funding sources. Although there has been a shift over time away from intensive psychosocial/psychotherapy and towards increasingly expensive psychopharmacotherapy for all three disorders, total direct medical costs of treatment for each of these three mental health disorders have been declining over time. However, a substantial portion of treatment is not supported by clinical evidence.
引用
收藏
页码:37 / 50
页数:14
相关论文
共 19 条
[11]   Extending indications for long-term pharmacotherapy: Opportunities and challenges [J].
Kane, JM .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (01) :1-2
[12]  
KELLER MB, 2002, PSYCHOPHARMACOL B, V36, P1
[13]  
KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8
[14]  
Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P1
[15]   Patterns of usual care for Schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) client survey [J].
Lehman, AF ;
Steinwachs, DM .
SCHIZOPHRENIA BULLETIN, 1998, 24 (01) :11-20
[16]   Quality of care in mental health: The case of schizophrenia [J].
Lehman, AF .
HEALTH AFFAIRS, 1999, 18 (05) :52-65
[17]  
LING DYC, 2004, NAT I MENT HLTH EC M
[18]   Spending for mental health and substance abuse treatment, 1996 [J].
McKusick, D ;
Mark, TL ;
King, E ;
Harwood, R ;
Buck, JA ;
Dilonardo, J ;
Genuardi, JS .
HEALTH AFFAIRS, 1998, 17 (05) :147-157
[19]   Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia - A randomized controlled trial [J].
Rosenheck, R ;
Perlick, D ;
Bingham, S ;
Liu-Mares, W ;
Collins, J ;
Warren, S ;
Leslie, D ;
Allan, E ;
Campbell, EC ;
Caroff, S ;
Corwin, J ;
Davis, L ;
Douyon, R ;
Dunn, L ;
Evans, D ;
Frecska, E ;
Grabowski, J ;
Graeber, D ;
Herz, L ;
Kwon, K ;
Lawson, W ;
Mena, F ;
Sheikh, J ;
Smelson, D ;
Smith-Gamble, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (20) :2693-2702